bioAffinity Technologies, Inc.(BIAF)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,750 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
BIAF Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for bioAffinity Technologies, Inc. (BIAF), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BIAF at 22.4/100 on a 32-signal composite quality model, placing it at rank #2,750 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), bioAffinity Technologies, Inc. reports quarterly revenue of $1.5M, net income of $-3.4M, free cash flow of $-3.3M. Top institutional holders of BIAF by reported 13-F value include SABBY MANAGEMENT, J. Safra Sarasin Holding AG, BlackRock, based on the most recent SEC filings. BIAF trades on the Nasdaq exchange and files with the SEC under CIK 1712762. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BIAF daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for bioAffinity Technologies, Inc. directly from SEC EDGAR. bioAffinity Technologies, Inc.'s 13F Pro composite quality score has ranged between 14 and 22 since 2026, currently 22.4 — an improving long-term trajectory across 9 quarterly and live scoring snapshots.
Revenue
Q2 2026
$1.5M
Net Income
Q2 2026
$-3.4M
Free Cash Flow
Q2 2026
$-3.3M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-34.2% YoYNet Income
-64.9% YoYOperating Income
-18.1% YoYEPS (Diluted)
+61.5% YoYTotal Assets
+68.3% YoYOp. Cash Flow
-28.4% YoYFree Cash Flow
-27.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $6.2M -34.2% | $9.4M +18.5% | $7.9M +14.5% | $6.9M | — | — |
| Net Income | $-14.9M -64.9% | $-9.0M -13.9% | $-7.9M +2.7% | $-8.2M -28.9% | $-6.3M | — |
| Operating Income | $-10.6M -18.1% | $-9.0M -12.3% | $-8.0M -98.8% | $-4.0M -81.8% | $-2.2M | — |
| EPS (Diluted) | $-8.66 +61.5% | $-22.50 -2372.5% | $-0.91 +49.7% | $-1.81 | — | — |
| Total Assets | $11.0M +68.3% | $6.5M -20.8% | $8.2M -32.5% | $12.2M +738.2% | $1.5M | — |
| Operating Cash Flow | $-9.3M -28.4% | $-7.3M -20.3% | $-6.0M -48.3% | $-4.1M -98.7% | $-2.0M | — |
| Free Cash Flow | $-9.4M -27.9% | $-7.3M -21.2% | $-6.1M -41.2% | $-4.3M | — | — |
Get alerted when BIAF's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for bioAffinity Technologies, Inc. including:
Top Institutional Holders of BIAF
SABBY MANAGEMENT, LLC
$296.9K365,647 shJ. Safra Sarasin Holding AG
$164.0K42,600 shBlackRock, Inc.
$80.2K98,777 shVANGUARD CAPITAL MANAGEMENT LLC
$45.1K55,543 shGEODE CAPITAL MANAGEMENT, LLC
$41.4K50,967 shVANGUARD FIDUCIARY TRUST CO
$25.2K31,071 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$21.8K26,870 shJANE STREET GROUP, LLC
$21.7K26,784 shSTATE STREET CORP
$19.6K24,086 shHRT FINANCIAL LP
$16.0K20,834 sh
| Fund | Value | Shares |
|---|---|---|
| SABBY MANAGEMENT, LLC | $296.9K | 365,647 |
| J. Safra Sarasin Holding AG | $164.0K | 42,600 |
| BlackRock, Inc. | $80.2K | 98,777 |
| VANGUARD CAPITAL MANAGEMENT LLC | $45.1K | 55,543 |
| GEODE CAPITAL MANAGEMENT, LLC | $41.4K | 50,967 |
| VANGUARD FIDUCIARY TRUST CO | $25.2K | 31,071 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $21.8K | 26,870 |
| JANE STREET GROUP, LLC | $21.7K | 26,784 |
| STATE STREET CORP | $19.6K | 24,086 |
| HRT FINANCIAL LP | $16.0K | 20,834 |
Companies Similar to BIAF
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
GULF RESOURCES, INC.
Firy Inc.
BIOMERICA INC
Ocean Power Technologies, Inc.
ANAVEX LIFE SCIENCES CORP.
Alchemy Investments Acquisition Corp 1
iBio, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put BIAF on your watchlist
Track score changes the day bioAffinity Technologies, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BIAF a good stock to buy?
13F Pro's AI-powered analysis of bioAffinity Technologies, Inc. (BIAF) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BIAF are available on the BIAF stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BIAF is classified as a small company.
Which hedge funds own BIAF?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BIAF. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of bioAffinity Technologies, Inc.'s investment landscape.